Skip to Main Content
Table 1.

Baseline patient characteristics.

CharacteristicsE7389-LF Q3W total (n = 12)E7389-LF Q2W total (n = 9)Overall (N = 21)
Median age, years (range) 51.5 (22–68) 59.0 (28–68) 58.0 (22–68) 
Sex, n (%) 
 Male 5 (41.7) 5 (55.6) 10 (47.6) 
 Female 7 (58.3) 4 (44.4) 11 (52.4) 
ECOG performance status, n (%) 
 0 6 (50.0) 5 (55.6) 11 (52.4) 
 1 6 (50.0) 4 (44.4) 10 (47.6) 
Median body surface area, m2 (range) 1.5 (1.3–1.9) 1.6 (1.4–2.4) 1.6 (1.3–2.4) 
Number of prior anticancer therapy regimens, n (%) 
 <2 1 (8.3) 4 (44.4) 5 (23.8) 
 2–4 10 (83.3) 4 (44.4) 14 (66.7) 
 ≥5 1 (8.3) 1 (11.1) 2 (9.5) 
CharacteristicsE7389-LF Q3W total (n = 12)E7389-LF Q2W total (n = 9)Overall (N = 21)
Median age, years (range) 51.5 (22–68) 59.0 (28–68) 58.0 (22–68) 
Sex, n (%) 
 Male 5 (41.7) 5 (55.6) 10 (47.6) 
 Female 7 (58.3) 4 (44.4) 11 (52.4) 
ECOG performance status, n (%) 
 0 6 (50.0) 5 (55.6) 11 (52.4) 
 1 6 (50.0) 4 (44.4) 10 (47.6) 
Median body surface area, m2 (range) 1.5 (1.3–1.9) 1.6 (1.4–2.4) 1.6 (1.3–2.4) 
Number of prior anticancer therapy regimens, n (%) 
 <2 1 (8.3) 4 (44.4) 5 (23.8) 
 2–4 10 (83.3) 4 (44.4) 14 (66.7) 
 ≥5 1 (8.3) 1 (11.1) 2 (9.5) 

Note: Percentages are based on the total number of patients in the safety analysis set within the relevant treatment group. Prior therapy excludes radiotherapy and surgery.

Abbreviations: E7389-LF, eribulin liposomal formulation; ECOG, Eastern Cooperative Oncology Group; Q2W, every 2 weeks; Q3W, every 3 weeks.

Close Modal

or Create an Account

Close Modal
Close Modal